US FDA investigates death tied to Takeda's blood disorder drug
21/11/2025 16:42
Nov 21 (Reuters) - The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' 4502.T blood disorder drug, the health regulator said on Friday. (Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Takeda Pharmaceutical
See all newsTakeda launches sleep disorder pill in the US after DEA clearance removes final hurdle (updated)
Brief: Takeda's Orzeyful Available In U.S. By Prescription To Treat Narcolepsy Type 1 In Adults
Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle
Takeda Pharmaceutical Company Limited reports results for the quarter ended September 30 - Earnings Summary
Table: Takeda Pharmaceutical Company Limited -6-MTH group results (IFRS)